New drug trial offers hope for rare, Life-Threatening immune disorder
NCT ID NCT07339345
Summary
This study is testing whether a drug called Golidocitinib can safely and effectively treat hemophagocytic lymphohistiocytosis (HLH), a rare and severe immune system disorder. It will involve 28 patients aged 14-70 who have HLH and are not currently suitable for a stem cell transplant. Researchers will measure how well the drug controls the disease and monitor for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
beijing Friendship Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100050, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.